DISCOUNT-ZERTIFIKAT - MODERNA | Market Closed - Boerse Frankfurt Warrants 15:39:41 2024-05-31 EDT | ||
| 78.77 EUR | -0.61% |
|
| 1 month | +4.07% | ||
| 3 months | +14.21% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 24-05-31 | 78.77 | -0.61% |
| 24-05-30 | 79.25 | -0.05% |
| 24-05-29 | 79.29 | +0.35% |
| 24-05-28 | 79.01 | -0.53% |
| 24-05-27 | 79.43 | -0.11% |
Real-time Boerse Frankfurt Warrants
Last update May 31, 2024 at 03:39 pm
More quotesStatic data
| Product type | Discount Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Société Générale
|
| WKN | SU6QCF |
| ISIN | DE000SU6QCF1 |
| Date issued | 2024-01-08 |
| Maturity | 2024-12-20 (201 Days) |
| Parity | 1 : 1 |
| Emission price | 68.87 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 79.66 € |
|---|---|
| Lowest since issue | 65.36 € |
| Spread | 0.02 € |
| Spread % | 0.03% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
142.6
USD
Average target price
139.9
USD
Spread / Average Target
-1.83%
- Stock Market
- Certificates
- Certificat
